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Abstract
Background: Lung cancer is one of the leading causes of death in Europe and the western world.
At present, diagnosis of lung cancer very often happens late in the course of the disease since
inexpensive, non-invasive and sufficiently sensitive and specific screening methods are not available.
Even though the CT diagnostic methods are good, it must be assured that "screening benefit
outweighs risk, across all individuals screened, not only those with lung cancer". An early non-
invasive diagnosis of lung cancer would improve prognosis and enlarge treatment options. Analysis
of exhaled breath would be an ideal diagnostic method, since it is non-invasive and totally painless.
Methods: Exhaled breath and inhaled room air samples were analyzed using proton transfer
reaction mass spectrometry (PTR-MS) and solid phase microextraction with subsequent gas
chromatography mass spectrometry (SPME-GCMS). For the PTR-MS measurements, 220 lung
cancer patients and 441 healthy volunteers were recruited. For the GCMS measurements, we
collected samples from 65 lung cancer patients and 31 healthy volunteers. Lung cancer patients
were in different disease stages and under treatment with different regimes. Mixed expiratory and
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indoor air samples were collected in Tedlar bags, and either analyzed directly by PTR-MS or
transferred to glass vials and analyzed by gas chromatography mass spectrometry (GCMS). Only
those measurements of compounds were considered, which showed at least a 15% higher
concentration in exhaled breath than in indoor air. Compounds related to smoking behavior such
as acetonitrile and benzene were not used to differentiate between lung cancer patients and healthy
volunteers.
Results: Isoprene, acetone and methanol are compounds appearing in everybody's exhaled breath.
These three main compounds of exhaled breath show slightly lower concentrations in lung cancer
patients as compared to healthy volunteers (p < 0.01 for isoprene and acetone, p = 0.011 for
methanol; PTR-MS measurements). A comparison of the GCMS-results of 65 lung cancer patients
with those of 31 healthy volunteers revealed differences in concentration for more than 50
compounds. Sensitivity for detection of lung cancer patients based on presence of (one of) 4
different compounds not arising in exhaled breath of healthy volunteers was 52% with a specificity
of 100%. Using 15 (or 21) different compounds for distinction, sensitivity was 71% (80%) with a
specificity of 100%. Potential marker compounds are alcohols, aldehydes, ketones and
hydrocarbons.
Conclusion: GCMS-SPME is a relatively insensitive method. Hence compounds not appearing in
exhaled breath of healthy volunteers may be below the limit of detection (LOD). PTR-MS, on the
other hand, does not need preconcentration and gives much more reliable quantitative results then
GCMS-SPME. The shortcoming of PTR-MS is that it cannot identify compounds with certainty.
Hence SPME-GCMS and PTR-MS complement each other, each method having its particular
advantages and disadvantages. Exhaled breath analysis is promising to become a future non-invasive
lung cancer screening method. In order to proceed towards this goal, precise identification of
compounds observed in exhaled breath of lung cancer patients is necessary. Comparison with
compounds released from lung cancer cell cultures, and additional information on exhaled breath
composition in other cancer forms will be important.
Background
Lung cancer is one of the leading causes of death in
Europe and the western world. At present, diagnosis of
cancer very often happens late in the course of the disease
since available diagnostic methods are not sufficiently
sensitive and specific.
There is strong evidence to suggest that particulate cancers
can be detected by molecular analysis of exhaled air [1-9].
Breath analysis represents a new diagnostic technique that
is without risk for the patient even if repeated frequently
and can provide information beyond conventional analy-
sis of blood and urine [9-16]. It may even be applied with
patients at an intensive care unit [17,18] or during surgery
[19]. Also real-time analysis of exhaled breath during an
ergometer test or during sleep are possible [15,20-22].
Current interest is not only focused on breath of lung can-
cer patients but also on emission of volatile organic com-
pounds (VOCs) from lung cancer tissue and lung cancer
cell cultures [23-26]. In our own investigations we
observed the release (or consumption) of various com-
pounds for the cancer cell lines A549, CALU-1 [25], NCI-
H2087 [26] and NCI-H1066 (Sponring A, Filipiak W,
Mikoviny T, Ager C, Schubert J, Miekisch W, Amann A,
Troppmair J: Release of volatile organic compounds from
the lung cancer cell line NCI-H1666 in vitro, submitted).
It would be most interesting to investigate jointly the
composition of exhaled breath of a particular patient and
in vitro release of compounds from cancer cells obtained
from the same patient (during a tumor resection).
Different analytical techniques have been used for analy-
sis of exhaled breath and headspace of cancer cell cultures.
One of the most useful technique is gas chromatography
and mass spectrometry (GCMS) [5,7,9,11,18,23,27-35].
This technique gives the most detailed analytical informa-
tion. Other techniques, such as sensor arrays [36] and pro-
ton transfer reaction mass spectrometry (PTR-MS) [8] or
selected ion flow tube mass spectrometry (SIFT-MS) [37-
39] do not need any preconcentration step and can work
in on-line mode, even in breath-to-breath resolution.BMC Cancer 2009, 9:348 http://www.biomedcentral.com/1471-2407/9/348
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In the present manuscript we present results obtained
with GCMS with preconcentration by solid phase micro-
extraction (SPME), and results obtained with PTR-MS.
Both techniques have their advantages and shortcomings.
PTR-MS measurements do not provide as much informa-
tion as GCMS, but the technique is more easy to handle.
Therefore the number of patients or volunteers investi-
gated by PTR-MS in our laboratory is much higher than
the number of persons investigated by GCMS.
It has been stated by Phillips et al., that 3481 different
compounds have been observed in exhaled breath. Some
of these compounds arise in higher concentrations in
inhaled air than in exhaled breath, having thus "negative
alveolar gradient" [40]. A total of 1753 different com-
pounds was described as having "positive alveolar gradi-
ent", i.e., arising in higher concentration in exhaled breath
than in inhaled air. Michael Phillips et al. used adsorption
of exhaled breath on adsorbents (solid phase extraction,
SPE) with subsequent thermodesorption (TD) and GC-
MS-analysis [5,7,27,41,42]. In their work, identification
of the peaks has been done by spectral library match only
without confirmation of retention time.
Among sample preparation methods, solid phase micro-
extraction (SPME) is one of the most frequently used.
SPME offers a simple and inexpensive alternative to pre-
concentration on sorbent tubes followed by thermal des-
orption (SPE). SPME was developed in the late 1980s by
Arthur and Pawliszyn [43,44]. This technique was success-
fully used in determination of volatile compounds in dif-
ferent matrices in environmental, toxicological, and
pharmacological analysis. SPME has been also applied to
analysis of VOCs in human breath [45].
For the validated identification of potential marker com-
pounds, we prepared calibration mixtures of the respec-
tive pure compounds in order to determine the retention
time and mass spectra. A particular focus of the present
investigation was the comparison of smokers vs. non-
smokers within the group of lung cancer patients, and the
exclusion of smoking-related compounds from compari-
sons between lung cancer patients and healthy controls.
We recently performed a PTR-MS investigation comparing
healthy smokers with healthy non-smokers and identified
7 different mass-to-charge ratios (in the range of 20 ≤ m/
z  ≤ 231) showing statistically significant differences
between smokers and non-smokers [34].
SPME-GCMS identifies compounds, but is a relatively
insensitive method. Hence compounds not appearing in
healthy volunteers' exhaled breath may appear at lower
concentrations below the limit of detection (LOD). In
addition, SPME-GCMS is only semiquantitative due to
competitive absorption on the SPME-fibre. PTR-MS, on the
other hand, does not need preconcentration and gives
much more reliable quantitative results. The shortcoming
of PTR-MS is that it cannot identify compounds with cer-
tainty, and several compounds may overlap on a particu-
lar mass-to-charge ratio [46]. Hence SPME-GCMS and
PTR-MS complement each other, each method having its
particular advantages and disadvantages.
Methods
GCMS analysis
The GCMS analysis was performed on Agilent 5975 Inert
XL MSD coupled with 7890 A gas chromatograph (Agi-
lent, Waldbronn, Germany) with split-splitless injector.
The temperature of injector was 290°C. The splitless time
was 1 min, while split ratio was 1:50. Helium was used as
a carrier gas at velocity 0.8 ml min-1. The MS analyses were
carried out in a full scan mode, with scan range 35 - 200
amu. A scan rate of 3.46 scan/s was applied. Electron
impact ionisation at energy 70 eV was used for every
measurement. The ion source, quadrupole and transfer
line temperatures were maintained at 230°C, 200°C and
200°C, respectively. The acquisition of chromatographic
data was performed by means of Chemstation (Agilent)
and mass spectrum library NIST 2005 (Gatesburg, USA)
was applied to identification. The 25 m × 0.32 mm × 5 μm
capillary column CP-Porabond-Q (Varian Inc., Middel-
burg, The Netherlands) was used. Oven temperature pro-
gramme was as follows: initial 90°C held for 7 min, then
ramped 7°C min-1 to 140°C, held for 7 min then ramped
15°C min-1 to 260°C and held for 10 min.
An automatic SPME holder with Carboxen/polydimethyl-
siloxane (CAR/PDMS) fiber of 75 μm thickness was pur-
chased from Supelco (Bellefonte, PA, USA). The sorption
and desorption of analytes have been performed automat-
ically by means of autosampler MPS 2XL (Gerstel, Mül-
heim an der Ruhr, Germany). SPME conditions were as
follow: extraction time of 10 min at a temperature of
37°C. Desorption of volatiles from the fiber was placed in
hot GC injector at 290°C, for 1 min. Prior every SPME
sorption, the fiber was preconditioned in small needle
heater (Gerstel, Mülheim an der Ruhr, Germany) at tem-
perature 290°C, for 5 min.
20 ml headspace vials, teflon coated rubber septa and
crimp caps were purchased from Gerstel (Mülheim an der
Ruhr, Germany). Helium and nitrogen of purity 6.0 (i.e.,
99.9999%) were purchased from Linde (Vienna, Austria)
and 3 Lit Tedlar bags from SKC (Eighty Four, PA, USA).
Gas tight syringes were purchased from Hamilton (Bon-
aduz, Switzerland) and 1 l gas bulb from Supelco (Belle-
fonte CA, USA).BMC Cancer 2009, 9:348 http://www.biomedcentral.com/1471-2407/9/348
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We defined signal to noise ratio of 3 as the limit of detec-
tion (LOD) and signal to noise ratios of 9 as the limit of
quantification (LOQ).
PTR-MS analysis
Volatile organic compounds with a volume ratio up to
1:1010(0.1 mm3 of the compound to 1 m3 air; 0.1 parts-per-
billion; 0.1 ppb) can be measured. The molecules are ion-
ized by proton transfer from H3O+-ions produced in the
ion source of the instrument with subsequent measure-
ment by a Quadrupol-Mass-Spectrometer [47-49]. The
proton transfer reaction only takes place if the proton
affinity of the analyte is higher than that of water, hence it
is possible to detect most aldehydes, ketones, alcohols,
acids, esters and many unsaturated aromatic as well as N
or S substituted hydrocarbons. The count rate of the pri-
mary ions (H3O+) was calculated taking the count rate at
m/z 21 and m/z 37 into consideration. For compounds
with unknown kinetic reaction constant, the nominal
constant k = 2 × 10-9 cm3 sec-1 allows to determine a first
estimate of the respective concentration (based on the
measured count rate).
To calculate the concentrations for the mentioned com-
pounds (acetone, benzene, isoprene, methanol) correctly,
we performed calibration series (under consideration of
the specific reaction rate constant k). The results of the
used calibration as well as the used reaction constant are
given in Table 1.
A high-sensitivity proton transfer reaction mass spectrom-
eter (hs-PTR-MS, 3 turbopumps; Ionicon Analytic GMBH,
Innsbruck, Austria) with Teflon rings (instead of Viton
rings) was used. The PTR-MS showed a count rate of the
primary ions (H3O+ ions) of ~1.5 × 107 counts per second.
The settings of the PTR-MS result in a count rate of
H2O.H3O+ at around 7.5 × 104 and the percentage of par-
asitic precursor ions O2
+ <1%, NO+<0.5% and NH4
+ < 8%
(the given values refer to dried, filtered room air, so-called
zero-air). For additional details see references [46,50].
Reagents and standards
Acetaldehyde, 2-butanone and 2-pentanone were bought
from Acros Organics (Geel, Belgium) 2-methyl-1-butene
from Chemsampco (Dallas, TX, USA), and rest of com-
pounds were purchased from Sigma-Aldrich (Steinheim,
Germany).
Preparation of gaseous standards
Calibration gases were prepared mostly by evaporation of
liquid compounds (except C4-C6 alkanes, 2-butene and
dimethyl ether) in a glass gas bulb. Before using, all bulbs
had been cleaned with methanol, dried in oven at 120°C
for at least 20 h, and then purged with ultra-clean nitrogen
for at least 10 min. Afterwards, bulbs were evacuated by
means of a vacuum pump for 10 min. Calibration vapour
mixture was obtained by injection of 1-3 μl of each com-
pound through membrane, using a GC syringe into a glass
bulb. After evaporation, appropriate amount of vapour
mixture was removed using gas tight syringe and intro-
duced into Tedlar® bags (SKC 232 Series, Eighty Four, PA,
USA) with 0.5, 1 or 1.5 L of nitrogen.
Human subjects: GCMS analysis
A cohort of 65 patients (28 smokers, 31 exsmokers and 6
nonsmokers) suffering from lung cancer at different stages
and in different treatment regimes (median age 63.0 years
and an age range of 37 - 84 years) was recruited. All indi-
viduals gave informed consent to participation in the
study. The patients completed a questionnaire describing
their current smoking status (active smokers, non-smok-
ers) and the time elapsed since their last smoke. The clas-
sification as smoker/non-smoker/ex-smoker is based on
the self-declaration of the patients. The amount of smok-
ing (in pack years) was determined.
Table 1: Kinetic reaction constants and calibration results for different compounds according to PTR-MS measurements.
Compound m/z kinetic rate constant
(taken from reference [55])
calibration factor*)
benzene 79 1.97·10-9 cm3 sec-1 0.95
isoprene 69 2.0·10-9 cm3 sec-1 2.26
acetone 59 3.9·10-9 cm3 sec-1 1.21
methanol 33 2.7·10-9 cm3 sec-1 0.69
acetonitrile 42 4.5·10-9 cm3 sec-1 1.24
*) The "calibration factor" is the factor used to correct concentrations which are initially determined using the kinetic rate constants as taken from 
reference [55]. The large "calibration factor" for isoprene is due to fragmentation of protonated isoprene (m/z 69) towards m/z 41.BMC Cancer 2009, 9:348 http://www.biomedcentral.com/1471-2407/9/348
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The lung cancer patients were compared with 31 healthy
volunteers (7 smokers, 2 exsmokers and 22 nonsmokers,
median age 38.0 years and an age range of 21 - 87 years),
who also gave informed consent to participation in the
study and declared their smoking habits.
All patients and volunteers consumed food not later than
one hour before breath sampling. No special dietary
regimes were applied. The samples were collected at dif-
ferent daytime independent of the time of meals and were
processed within 6 hours at most. The study was approved
by the local ethics committee of Innsbruck Medical Uni-
versity.
Human subjects: PTR-MS analysis
A cohort of 220 lung cancer patients (68 smokers, 129
exsmokers and 23 nonsmokers) at different stages and in
different treatment regimes (median age 64.4 years and an
age range of 39 - 83 years) and 441 healthy volunteers (84
smokers, 86 exsmokers and 271 nonsmokers, median age
54 years and an age range of 17 - 91 years) was recruited.
Recruitment and protocol is identical to the patients and
volunteers measured by GCMS.
Sampling of exhaled breath
Samples of mixed breath gas were collected in Tedlar bags
(SKC Inc, Eighty Four, PA) with parallel collection of
ambient air (also in Tedlar bags). Breath gas samples were
obtained after a ~5 minutes sitting of a volunteer. Each
subject provided 1 or 2 breath samples by use of a straw.
All samples were processed within 3-6 hours. We collected
mixed alveolar breath (instead of alveolar breath) in order
to find also compounds directly released from the lungs.
Before collection of breath, all bags were thoroughly
cleaned to remove any residual contaminants by flushing
with nitrogen gas (purity of 99.9999%), and then finally
filled with nitrogen and heated at 85°C for more than 8
hours with a complete evacuation at the end.
All compounds detected in breath were compared to the
ambient air and only compounds with concentrations at
least 15% higher than in ambient air concentrations were
reported. 18 ml of gas sample has been transferred to 20
ml volume evacuated glass vials, and equilibrated with
nitrogen gas.
Here we determined VOCs in exhaled breath of lung can-
cer patients. We restrict ourselves to compounds which
show at least 15% higher concentrations in exhaled
breath as compared to inhaled air. In particular, we
exclude compounds which show lower concentration in
exhaled breath than in inhaled air. Our experience
showed that different rooms show quite different indoor
air composition, which is particularly pronounced in clin-
ical environments. The threshold of 15% was arbitrarily
chosen.
Smokers evaluation (GCMS measurements)
For each compound found, we determined the propor-
tion of lung cancer patients in whose exhaled breath the
compound appears, separately for smokers, exsmokers
and non-smokers, see Figure 1. Putting smokers into one
class and combining exsmokers and non-smokers into the
other class, the respective proportions, namely propor-
tionsmoker and proportionexsmoker  and  non-smoker were com-
puted for appearance of each compound. The p-value for
the null hypothesis "proportionsmoker  = proportionex-
smoker  and  non-smoker"  was computed according to the
method proposed by Agresti and Caffo [51]. Statistical
results are considered to be significant if p <0.05.
Group comparisons (PTR-MS measurements)
The non-parametric Kruskal-Wallis test (equivalent to the
Wilcoxon rank sum test) was used for all comparisons of
concentrations in two groups. For all comparisons, the
null-hypothesis was that the concentrations of compared
Compounds observed in exhaled breath of cancer patients  which are related to smoking behavior (GCMS) Figure 1
Compounds observed in exhaled breath of cancer 
patients which are related to smoking behavior 
(GCMS). Only those measurements have been considered, 
which show at least 15% higher concentration in exhaled air 
than in indoor air. The relative proportions for observations 
with respect to smoker patients (red), ex-smoker patients 
(blue) and non-smoker patients (green) is shown. Nine com-
pounds (blue) were identified by retention time and by spec-
tral library identification. One compound, namely 1,3-
cyclopentadiene was not commercially available and there-
fore only identified by spectral library match. Acetonitrile 
and toluene arise in almost every smokers' exhaled breath. p-
Values computed according to the method of Agresti and 
Caffo [51] are smaller than 0.0001 with the exception of 2-
methyl-1-butene and 1,4-pentadiene, where p < 0.05.BMC Cancer 2009, 9:348 http://www.biomedcentral.com/1471-2407/9/348
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groups are equally distributed. Statistical results are con-
sidered to be significant if p <0.01. We chose this limit
(instead of p < 0.05) because of the large number of sub-
jects in the cohort investigated by PTR-MS (220 lung can-
cer patients, 441 healthy controls).
Compounds excluded for distinction of lung cancer 
patients from healthy volunteers
Certain compounds may arise in relatively high concen-
trations in indoor air. Typical examples are isopropanol or
limonene (from cleaning agents) or p-xylene (in hospital
indoor air). Other compounds like cineole, menthol, p-
cymene or ethanol may be contained in toothpaste, can-
dies or foodstuff. Phenol and N,N-dimethyl acetamide are
released from Tedlar bags and carbon disulfide is fre-
quently released by GCMS septa. Halogenated com-
pounds like trichloroethylene, acetylbromide or 1,1-
difluoroethane have to be treated with care. N,N-dimethyl
formamide may also have a hospital-related background.
Other compounds like acetonitrile are typical for smoking
(see Results Section). These mentioned compounds were
excluded when trying to distinguish lung cancer patients
from healthy volunteers with respect to VOC concentra-
tion patterns in exhaled breath.
Results
Patient characterization
The demographic data of patients, volunteers and the his-
tologic subtypes of lung cancer are presented in Table 2, 3,
4, and 5.
Concentrations of volatile organic compounds as 
determined by PTR-MS
The distribution of concentrations for benzene, isoprene,
acetone and methanol was determined by PTR-MS. The
substances isoprene, acetone and methanol are the main
components of exhaled breath.
The results for benzene are shown in Figure 2. The median
concentrations of benzene are increased in smokers (CA-
smoker 2.9 ppb; control-smoker 2.4 ppb) as compared to
non-smokers and exsmokers (CA-nonsmoker/exsmoker 0.9
ppb, control-nonsmoker/exsmoker 1.1 ppb). We observe a
small difference between lung cancer patients and con-
trols: statistically significant for the non/ex-smoker sub-
groups (p = 0.002), but not for the smoker-subgroup (p =
0.469).
The results for isoprene are shown in Figures 3 and 4. The
median concentrations of isoprene are lower in lung can-
cer patients (81.5 ppb) than in healthy controls (105.2
ppb), with a p-value p < 0.01. Since isoprene shows age
and gender effects [33], we differentiated also with respect
to gender, see Table 6: For male persons we observed
median concentrations of 133.7 ppb in controls which are
younger than 50 years, 100.0 ppb in controls which are
older than 50 years, and 87.1 ppb in lung cancer patients.
In female persons we observed median concentrations of
103.9 ppb in controls which are younger than 50 years,
98.1 ppb in controls which are older than 50 years, and
72.9 ppb in lung cancer patients. Additional information
Table 2: Demographic data related to current smoking status for control and cancer patients measured by PTR-MS*).
Smokers Non-smokers Ex-smokers Total
nA g e
Median (range)
nA g e
Median (range)
nA g e
Median (range)
nA g e
Median (range)
Control Female 56
(55)
43
(18-81)
176
(171)
57.5
(17-91)
39
(37)
55
(25-85)
271
(263)
53.83
(17-91)
Male 28
(26)
46
(23-77)
95
(91)
53
(24.5-86)
47
(47)
64
(33-88)
170
(164)
56.25
(23-88)
Total 84
(81)
44
(18-81)
271
(262)
57
(17-91)
86
(84)
61.25
(25-88)
441
(427)
54
(17-91)
CA-
Patients
Female 23
(23)
55
(46-77)
18
(17)
71
(39-82.5)
39
(39)
64.5
(44-83)
80
(79)
63
(39-83)
Male 45
(43)
60
(40-77)
5
(5)
61
(51-70)
90
(88)
66.3
(46.4-81)
140
(136)
65
(40-81)
Total 68
(66)
58
(40-77)
23
(22)
67
(39-82.5)
129
(127)
66
(44-83)
220
(215)
64.4
(39-83)
*) Some measurements for PTR-MS were excluded (because of device variations), in brackets the number of subjects were at least 1 measurement 
was valid is given.BMC Cancer 2009, 9:348 http://www.biomedcentral.com/1471-2407/9/348
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on lung cancer patients with and without radiotherapy are
given in Figure 4: Lung cancer patients undergoing a radi-
otherapy show a slightly higher concentration of isoprene
than lung cancer patients without radiotherapy.
The results for acetone are shown in Figure 5: The median
concentrations of acetone are lower in lung cancer
patients (458.7 ppb) than in healthy controls (627.5
ppb), with a p-value p < 0.01.
The results for methanol are shown in Figure 6: The median
concentrations of methanol are lower in lung cancer
patients (118.5 ppb) than in healthy controls (142.0
ppb), with a p-value p = 0.011.
Volatile organic compounds in lung cancer patients 
observed by GCMS
We observed altogether 103 volatile organic compounds
(VOCs) in exhaled breath of lung cancer patients. We do
not claim that all of these compounds are endogenously
produced. These compounds were identified by spectral
library match. For 84 of these 103 compounds we con-
firmed identification by comparison of retention times
with native standards.
Limit of detection (LOD) with our SPME-GCMS method
was determined for 43 different compounds [35]. The
lowest LOD was 0.7 ppb (for isoprene), the highest LOD
was 17.2 ppb (for 3-Butyn-2-ol). The median LOD of 43
compounds was 2.4 ppb.
The appearance of the following compounds is influenced
by smoking habits: toluene, benzene, acetonitrile, 2-
methyl furan, 2,5-dimethyl furan, furan, 1,3-cyclohexadi-
ene, 1,3-cyclopentadiene, 2-methyl-1-butene, 1,4-penta-
diene. p-Values computed according to the method of
Agresti and Caffo [51] are smaller than 0.0001 with the
exception of 2-methyl-1-butene and 1,4-pentadiene,
where p < 0.05. The proportion of lung cancer patients
showing these compounds in their exhaled breath is
shown in Figure 1 for smokers, ex-smokers and non-
smokers. Apart from 1,3-cyclopentadiene (which is not
Table 3: Demographic data related to current smoking status for control and cancer patients measured by GCMS.
Smokers Non-smokers Ex-smokers Total
nA g e
Median (range)
nA g e
Median (range)
nA g e
Median (range)
nA g e
Median (range)
Control Female 4 52.5 (21 - 65) 10 51.0 (23 - 87) 2 57.5 (30 - 85) 16 51.0 (21 - 87)
Male 3 26.0 (25 - 28) 12 35.5 (27 - 68) 0 15 33.0 (25 - 68)
Total 7 28.0 (21 - 65) 22 41.5 (23 - 87) 2 57.5 (30 - 85) 31 38.0 (21 - 87)
CA-patients Female 10 60.5 (37 - 84) 5 59.0 (48 - 82) 9 58.0 (48 - 72) 24 58.5 (37 - 84)
Male 18 59.0 (45 - 78) 1 79.0 (79 - 79) 22 65.0 (51 - 79) 41 64.0 (45 - 79)
Total 28 59.0 (37 - 84) 6 66.5 (48 - 82) 31 65.0 (48 - 79) 65 63.0 (37 - 84)
Table 4: Histology of lung cancers (for patients whose exhaled 
breath was investigated by GCMS)
Small cell 15
Non-small cell adenocarcinoma 25
epidermoid carcinoma 17
large cell carcinoma 1
mixed epidermoid-large cell carcinoma 4 47
Mesothelioma 1
Carcinoid 2
Table 5: Histology of lung cancers (for patients whose exhaled 
breath was investigated by PTR-MS)
Small cell 39
Non-small cell adenocarcinoma 98
epidermoid carcinoma 64
large cell carcinoma 7 169
Mesothelioma 2
Carcinoid 5
Others 5BMC Cancer 2009, 9:348 http://www.biomedcentral.com/1471-2407/9/348
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commercially available), all these smoking-related com-
pounds were not only identified by spectral library match,
but also by comparison of GCMS retention time with that
of standards based on the respective pure compound.
All the compounds related to smoking behavior were
excluded from the list of compounds which are thought to
be specific for lung cancer.
VOCs specific for lung cancer patients (PTR-MS)
For isoprene, acetone and methanol we observe lower
concentrations in exhaled breath of lung cancer patients
as compared to healthy volunteers (see Discussion Sec-
tion).
VOCs specific for lung cancer patients (GCMS)
A comparison of the results of our cohort of 65 lung can-
cer patients with those of 31 healthy volunteers revealed
differences in the concentration patterns. Sensitivity for
detection of lung cancer patients based on 4 different
compounds (or 15 different compounds or 21 different
compounds) not arising in exhaled breath of healthy vol-
unteers was 52% (71% and 80%). Compounds specific
for smoking were not included in these sets. The three used
sets of compounds were increasing, i.e.,
The smallest set-A of 4 compounds consisted of 2-
butanone, benzaldehyde, 2,3-butanedione, 1-propanol.
The other sets of compounds are listed in Table 7. All the
21 compounds used here for detection of lung cancer
patients were not observed in healthy controls at concen-
trations at least 15% higher in exhaled breath than in
indoor air (as detected by SPME with its relatively high
LOD). Hence specificity is always 100% for all three sets
of compounds.
Figure 7 illustrates the concentration patterns of selected
compounds (including the above set-A of 4 compounds)
for lung cancer smokers, lung cancer ex-smokers and lung
cancer non-smokers as compared with healthy smokers,
healthy ex-smokers and healthy non-smokers. Some com-
pounds like isoprene and acetone arise in everybody's
exhaled breath. Some compounds like acetonitrile are typ-
ical for smoking behavior. Some compounds were
observed only in lung cancer patients (e.g., the sets A-C of
compounds given in Table 7).
Discussion
The following points characterize our investigation and
are discussed here:
(A) No differences of concentrations (concentrationex-
piratory - concentrationinspiratory) between exhaled breath
and indoor air were considered. Only expiratory con-
centrations (concentrationexpiratory) were considered.
All our results refer to measurements which showed at
least 15% higher concentrations in exhaled breath
than in indoor air. If indoor air concentrations of
some compound was higher than the concentration in
exhaled air, the respective compound was not consid-
ered for the particular patient/volunteer in question.
(B) We excluded certain compounds from use for the
distinction between lung cancer patients and healthy
volunteers, because these compounds may be related
to artefacts. These compounds may be observed due to
indoor air contamination, cleaning agents, tooth-
paste, candies or foodstuff, compounds being released
from tubings, Tedlar bags or GCMS septa etc, see Table
8.
(C) We were interested in compounds related to
smoking behavior, but did not use them to distinguish
between lung cancer patients and healthy volunteers.
set-A   compounds set-B   compounds set-C   compoun () ( ) ( 41 52 1 ⊂⊂ d ds).
Concentration distributions of benzene (determined by PTR- MS) in exhaled breath of lung carcinoma patients (smokers:  red; non/ex-smoker: magenta) and healthy volunteers (smok- ers: blue; non/ex-smokers: green) Figure 2
Concentration distributions of benzene (determined 
by PTR-MS) in exhaled breath of lung carcinoma 
patients (smokers: red; non/ex-smoker: magenta) 
and healthy volunteers (smokers: blue; non/ex-smok-
ers: green). The concentration is shown in logarithmic scal-
ing. Benzene concentration is increased in the subgroups of 
smokers and therefore a marker for smoking behavior. The 
median values for benzene in human breath have been deter-
mined as follows: CA-patients-non/ex-smoker 0.9 ppb, control-
non/ex smokers 1.1 ppb (significant difference according to 
Kruskal-Wallis test: p-value 0.002); CA-patients-smoker 2.9 
ppb, control-smokers 2.4 ppb (no statistical significant differ-
ence according to Kruskal-Wallis test: p-value 0.469). The 
difference in smoking behaviour (between smoker and non/
ex-smoker) is statistically significant for the control group (p-
value < 1*10-5) as well as for the CA-patients (p-value < 
1*10-5).BMC Cancer 2009, 9:348 http://www.biomedcentral.com/1471-2407/9/348
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(D) We determined retention times of as many com-
pounds as possible based on standards prepared from
the respective pure compound. In total, we deter-
mined retention times of ~220 compounds with
respect to our SPME-GCMS measurement protocol.
For the present study with 103 observed compounds
altogether 84 compounds were confirmed by reten-
tion time. We clearly indicate for each compound if it
was identified by spectral library match only, or addi-
tionally by determination of retention time.
(E) We strictly observed the policy that one GCMS-
peak corresponds to one compound.
(F) We used Tedlar bags (polyvinylfluoride), glass
vials and Teflon tubings. Our experience is that these
materials have very limited release of volatile com-
pounds (phenol and N,N-dimethyl acetamide for Ted-
lar bags). Other tubings than Teflon may release
plasticizers. Phillips et al. [6] mention among marker
compounds plasticizers such as "2,2,4-Trimethyl-1,3-
pentanediol diisobutyrate", "Pentanoic acid, 2,2,4-tri-
methyl-3- carboxyisopropyl, isobutyl ester" and "Pro-
panoic acid, 2-methyl-, 1-(1,1- dimethylethyl)-2-
methyl- 1,3-propanediyl ester". It might be that these
compounds are not of biological origin, but have their
origin in the release of these compounds from some
tubing system.
(G) All our GCMS-experiments described here were
done using SPME. This is not as sensitive as solid
phase extraction with subsequent thermodesorption.
If measurements are done with higher sensitivity, cer-
tain compounds may be present in exhaled breath of
healthy volunteers, even if we do not detect them by
SPME.
The approach (A) for us is physiologically more informa-
tive than taking differences in concentrations whenever a
VOC behaves like carbon dioxide: the concentration of
CO2 in exhaled air (about 4%) is, within the normal
inspiratory range, independent of the CO2 concentration
in inhaled air (0.03% to 2% in indoor air) [52]. Only the
exhaled concentration of CO2 (and not the difference of
concentrations in exhaled breath and indoor air) refers to
the physiological state of the human body. Nevertheless,
compounds showing higher concentration in exhaled
breath than in indoor air are not exclusively the result of
metabolic processes, but can also be stored in different
body compartments as a consequence of particular food
consumption, smoking, medication, toothpaste, cosmet-
ics and other sources. Some compounds, which could be
important as potential biomarkers, are widespread in
ambient air especially in a clinical environment, e.g. iso-
propanol.
Table 6: Statistical results related to the concentration of isoprene in exhaled breath (PTR-MS), whose concentrations show gender- 
and age-specific behavior [33].
compared populations restricted to population p-value*)
H0: equal mean values for 
log-transformed 
concentrations;
H1: not equal mean values
median
concentration of
isoprene for
population (A)
median
concentration of isoprene 
for
population (B)
Female (population A)
vs.
Male (population B)
Control, younger 50 years 0.0005 103.9 ppb 133.7 ppb
Control, older 50 years 0.940, not significant 98.1 ppb 100.0 ppb
CA-patients 0.0008 72.9 ppb 87.1 ppb
Control, younger 50 years 
(A) vs.
control, older 50 years (B)
Female 0.564, not significant 103.9 ppb 98.1 ppb
Male 0.0002 133.7 ppb 100.0 ppb
CA-patients (A) vs.
control, older 50 years (B)
Female 1.0*10-5 72.9 ppb 98.1 ppb
Male 0.022, not significant 87.1 ppb 100.0 ppb
*) according Kruskal-Wallis test, alpha-level = 0.01BMC Cancer 2009, 9:348 http://www.biomedcentral.com/1471-2407/9/348
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Several compounds were excluded from consideration (B)
due to possible indoor air contamination (p-xylene, iso-
propanol, N,N-dimethyl formamide), due to their release
by Tedlar bags (N,N-dimethyl acetamide, phenol) or
GCMS septa (carbon disulfide), due to their appearance in
cleaning agents or foodstuff (limonene, p-cymene, men-
thol) and due to potentially exogenous origin (halogen-
ated compounds), see Table 8. The compound N,N-
dimethyl-acetamide is released from Tedlar bags and the
compound carbon disulfide (CS2) is released by GCMS-
septa. Some compounds need a more detailed investiga-
tion, such as the ester methyl acetate. This compound
might appear in exhaled breath of healthy volunteers at
low concentrations (ca. 1 ppb), and has been demon-
strated to increase in concentration with increasing car-
diac output (in one volunteer, only, results not shown).
Other compounds like 2-methyl pentane and 3-methyl
pentane are potentially interesting for cancer screening,
but might be released from certain types of GCMS-septa,
even though not released by the septa used in the present
investigation. Ethyl-benzene is a potentially interesting
compound but excluded here because it is one of the vol-
atile BTEX-compounds (= benzene, toluene, ethyl-ben-
zene, xylene) appearing in gasoline, which are ubiquitous
due to the contamination of soil and groundwater with
these compounds.
For distinction between lung cancer patients and healthy
volunteers we also excluded (C) all the compounds
related to smoking behavior. A typical example is ace-
Concentration distributions of isoprene (determined by  PTR-MS) in exhaled breath of lung carcinoma patients (CA- patients-female: red; CA-patients-male: dark red) and healthy  volunteers (control < 50 years, female: green; control < 50  years, male: dark green; control > 50 years, female: blue; control  > 50 years, male: dark blue) Figure 3
Concentration distributions of isoprene (determined 
by PTR-MS) in exhaled breath of lung carcinoma 
patients (CA-patients-female: red; CA-patients-male: 
dark red) and healthy volunteers (control < 50 years, 
female: green; control < 50 years, male: dark green; 
control > 50 years, female: blue; control > 50 years, 
male: dark blue). The concentration is shown in logarith-
mic scaling. The median concentration of isoprene in exhaled 
breath of cancer patients is 81.5 ppb, whereas in healthy con-
trols it is 105.2 ppb. For females, the median concentration 
for isoprene in breath is: for CA-patients 72.9 ppb; for con-
trol < 50 years 103.9 ppb and for controls > 50 years 98.1 
ppb. For males, the median concentration for isoprene in 
breath is: for CA-patients 87.1 ppb; for control < 50 years 
133.7 ppb and for controls > 50 years 100.0 ppb. Separated 
for gender, the difference for CA-patients and control, older 
50 years was statistically significant for females: p-value < 
1.0*10-5, but not for males: p-value = 0.022.
Concentration distributions of isoprene (determined by  PTR-MS) in exhaled breath of lung carcinoma patients  treated with radiotherapy (CA-patients-radiotherapy-female (n  = 22): magenta; CA-patients-radiotherapy-male (n = 36): green),  carcinoma patients not treated with radiotherapy (CA- patients-no radiotherapy-female (n = 50): cyan; CA-patients-no  radiotherapy-male (n = 88): black) and healthy volunteers (con- trol < 50 years, female (n = 121): dark red; control < 50 years,  male (n = 70): dark blue; control > 50 years, female (n = 142):  red; control > 50 years, male (n = 94): blue) Figure 4
Concentration distributions of isoprene (determined 
by PTR-MS) in exhaled breath of lung carcinoma 
patients treated with radiotherapy (CA-patients-radi-
otherapy-female (n = 22): magenta; CA-patients-radio-
therapy-male (n = 36): green), carcinoma patients not 
treated with radiotherapy (CA-patients-no radiother-
apy-female (n = 50): cyan; CA-patients-no radiotherapy-
male (n = 88): black) and healthy volunteers (control < 
50 years, female (n = 121): dark red; control < 50 years, 
male (n = 70): dark blue; control > 50 years, female (n = 
142): red; control > 50 years, male (n = 94): blue). 19 
CA-patients (7 female, 12 male) were excluded from consid-
eration, because they did not clearly fit into one of the two 
groups (with/without radiotherapy). The concentration is 
shown in logarithmic scaling. For females, the median con-
centration for isoprene in breath is: for CA-patients-radio-
therapy 85.1 ppb; for CA-patients-no radiotherapy 68.1 ppb; 
for control < 50 years 103.9 ppb and for controls > 50 years 
98.1 ppb. For males, the median concentration for isoprene 
in breath is: for CA-patients-radiotherapy 89.9 ppb; for CA-
patients-no radiotherapy 85.4 ppb; for control < 50 years 
133.7 ppb and for controls > 50 years 100.0 ppb. A discus-
sion of age- and gender effects in healthy volunteers is given 
in reference [33].BMC Cancer 2009, 9:348 http://www.biomedcentral.com/1471-2407/9/348
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tonitrile. The concentration of acetonitrile in exhaled
breath of smokers is around ~30-60 ppb, whereas the con-
centration in exhaled breath of non-smokers is low (~2-5
ppb).
Identification based on spectral library match only may be
misleading (D). We therefore add retention time for
proper identification and have built up a database of ~300
physically available compounds (stored in a refrigerator).
Since many of the exhaled compounds observed here
have never been described in the biochemical literature, it
is of utmost importance for further biochemical investiga-
tions to confirm the peak attribution with certainty.
Therefore identification of peaks based on calibration
mixtures (starting from pure compounds) is necessary.
Only such a validated identification allows to investigate
the biochemical background of the observed compound
by, e.g., 13C-labelling of metabolic precursors.
We strictly identify only one compound per GCMS-peak
(E). Even though this may sound trivial, we know that
other researchers attribute more than one compound to a
peak (to circumvent the difficulty of chosing one among
the several suggestions given by the exclusive use of spec-
tral library identification without checking the retention
time).
Collection of exhaled breath has to be done with great
care. In particular, all alternative exogenous sources of
volatiles should be avoided. We therefore use only Teflon
tubings (F) and avoid all other materials, which might
release plasticizers.
Altogether 53 compounds were observed in (some) can-
cer patients but not in healthy volunteers at our sensitivity
level of GCMS-SPME. By considering different sets of can-
didates for cancer marker compounds (set-A: 4 com-
pounds; set-B: 15 compounds; set-C: 21 compounds), we
arrived at a specificity of 100% and a sensitivity of 52%
(71% and 80%, respectively for the different sets of com-
pounds). Considering all 53 compounds would not
increase the sensitivity. Our primary aim was not to
achieve high sensitivity for detection of lung cancer, but to
identify the compounds observed in exhaled breath of
lung cancer patients (of all disease stages) in a careful
manner, taking into account not only spectral library
match, but also retention time using standards prepared
from the respective pure compounds. The mentioned 21
compounds do not include smoking-related compounds
and do not  include the compounds given in Table 8,
which were excluded from consideration. The compounds
which we presented here as candidates for cancer marker
compounds were not tested in an independent cohort.
Concentration distributions of acetone (determined by PTR- MS) in exhaled breath of lung carcinoma patients (red) and  healthy volunteers (green) Figure 5
Concentration distributions of acetone (determined 
by PTR-MS) in exhaled breath of lung carcinoma 
patients (red) and healthy volunteers (green). The 
concentration is shown in logarithmic scaling. The median 
concentration of acetone in exhaled breath of cancer 
patients is 458.7 ppb, whereas in healthy controls it is 627.5 
ppb. (significantly different according Kruskal-Wallis test; p-
value = 0.001).
Concentration distributions of methanol (determined by  PTR-MS) in exhaled breath of lung carcinoma patients (red)  and healthy volunteers (green) Figure 6
Concentration distributions of methanol (deter-
mined by PTR-MS) in exhaled breath of lung carci-
noma patients (red) and healthy volunteers (green). 
The concentration is shown in logarithmic scaling. The 
median concentration of methanol in exhaled breath of can-
cer patients is 118.5 ppb, whereas in healthy controls it is 
142.0 ppb. (not significantly different according Kruskal-Wal-
lis test; p-value = 0.011).BMC Cancer 2009, 9:348 http://www.biomedcentral.com/1471-2407/9/348
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SPME-GCMS identifies compounds, but is a relatively
insensitive method. Hence compounds not appearing in
healthy volunteers' exhaled breath may appear at lower
concentrations below the limit of detection (LOD). In
addition, SPME-GCMS is only semiquantitative due to
competitive absorption on the SPME-fibre. PTR-MS, on the
other hand, does not need preconcentration and gives
much more reliable quantitative results. The shortcoming
of PTR-MS is that it cannot identify compounds with cer-
tainty, and several compounds may overlap on a particu-
lar mass-to-charge ratio [46]. Hence SPME-GCMS and
PTR-MS complement each other, each method having its
particular advantages and disadvantages.
In  PTR-MS measurements we looked at relatively large
groups of lung cancer patients (n = 220) and healthy vol-
unteers (n = 441). We use tentative identifications for ben-
zene (m/z 79), isoprene (m/z 69), acetone (m/z 59) and
methanol (m/z 33). Benzene clearly is a compound
related to smoking behavior. The respective concentra-
Table 7: Potential marker compounds for lung cancer (GCMS), set-A consisting of 4 different compounds, set-B of 15 compounds, and 
set-C of 21 compounds.
compound name CAS-number checked for retention time
compounds for set A 2-Butanone 78-93-3 1
Benzaldehyde 100-52-7 1
2,3-Butanedione 431-03-8 0
1-Propanol 71-23-8 1
add. compounds for set B 2-Butanone, 3-hydroxy- 513-86-0 1
3-Butyn-2-ol 2028-63-9 1
Butane, 2-methyl- 78-78-4 1
2-Butene, 2-methyl- 513-35-9 1
Acetophenone 98-86-2 1
1-Cyclopentene 142-29-0 1
Methyl propyl sulfide 3877-15-4 1
Urea, tetramethyl- 632-22-4 1
n-Pentanal 110-62-3 1
1,3-Cyclopentadiene, 1-methyl- 96-39-9 0
2-Butanol, 2,3-dimethyl- 594-60-5 1
add. compounds for set C Isoquinoline, 1,2,3,4-tetrahydro- 91-21-4 0
Undecane, 3,7-dimethyl- 17301-29-0 0
Benzene, cyclobutyl- 4392-30-7 0
Butyl acetate 123-86-4 1
Ethylenimine 151-56-4 0
n-Undecane 1120-21-4 0BMC Cancer 2009, 9:348 http://www.biomedcentral.com/1471-2407/9/348
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tions of isoprene, acetone and methanol are lower in lung
cancer patients as compared to healthy volunteers. This
might partly be an effect of age (as in isoprene [33]), and
partly might be due to lower exhalation force in lung can-
cer patients.
Our healthy controls are younger than patients, and this is
particularly so for the GCMS-measurements. Also, no dis-
ease controls have been considered, e.g., controls suffer-
ing from lung diseases such as COPD. Certainly age,
gender and lung diseases (other than lung cancer) are con-
founding variables, which have to be evaluated very care-
fully, cf. refs [33,50].
We did not find pronounced differences in composition
of exhaled breath between different stages and different
treatment regimes. Small differences occur for isoprene,
acetone and methanol (PTR-MS measurements). We dis-
cussed isoprene in more detail as an illustrative example
(see Figures 3, 4 and Table 6): A statistically significant dif-
ference in concentration of isoprene was observed
between female lung cancer patients and female healthy
controls (p < 0.00001). For male lung cancer patients, the
respective p-value (p = 0.022) was not below our chosen
treshold (namely 0.01) for significance.
The biochemical background of the compounds observed
in exhaled breath is largely unknown and needs further
elucidation in the future before using certain compounds
as biomarkers. In order to be on the right track, it is abso-
lutely compelling to have a proper identification of the
compounds observed by GC-MS analysis. It will also be
desirable to determine the kinetic rate constants for the
exchange of compounds (e.g., isoprene) between different
compartments of the body. This is, in particular, impor-
tant for compounds which are lipophilic, such as isoprene
[53,54] or such as methylated hydrocarbons.
The final goal of our investigations is the development of
a clinically applicable screening test for detection of lung
cancer. Even though our results are promising, there is still
a long way to go. We shall need more detailed informa-
tion about the composition of exhaled breath in cohorts
suffering from other carcinomas and other lung diseases,
and get information on compounds released from pri-
mary cancer cell cultures. Preferably combined informa-
tion on primary cancer cell cultures and exhaled breath of
one and the same patient should be collected.
Conclusion
Exhaled breath analysis is a promising diagnostic method
for detection of lung cancer. Typical compounds arising in
everybody's exhaled breath are isoprene, acetone and
methanol, which exhibit decreased concentrations in
breath of lung cancer patients as compared to healthy con-
trols. Many other compounds arise in lung cancer patients
only (when detected by SPME-GCMS with a lower detec-
tion limit of ~2-3 ppb). An important issue is the vali-
dated identification of volatile compounds observed in
breath by comparison with commercially available pure
compounds, since many observed compounds from
exhaled breath have not been considered before in medi-
cal or biochemical context.
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This figure shows the distribution of appearance in exhaled  breath of cancer patients (smokers, exsmokers and non- smokers) for 60 compounds out of altogether 103 com- pounds (GCMS) Figure 7
This figure shows the distribution of appearance in 
exhaled breath of cancer patients (smokers, exsmok-
ers and non-smokers) for 60 compounds out of alto-
gether 103 compounds (GCMS). Isopropanol is not 
appearing in this figure, because it usually shows higher con-
centrations in indoor air than in exhaled air. Carbondisulfide 
is not appearing in this figure, because it may be released 
from septa used for SPME investigations. Names of those 
compounds which have been identified not only by spectral 
library match but in addition by comparison with retention time 
of the pure respective compound, are shown in magenta color. 
Names of compounds only identified by spectral library 
match are shown in black color. The columns of four sug-
gested marker compounds (set-A) are shown between white 
vertical lines. These compounds appear in cancer patients 
(smokers, ex-smokers and non-smokers), but do not appear 
in exhaled breath of healthy volunteers with concentrations 
above the limit of detection (LOD).BMC Cancer 2009, 9:348 http://www.biomedcentral.com/1471-2407/9/348
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Table 8: List of compounds which were excluded from consideration for the differentiation of lung cancer patients from healthy 
controls
1,1-difluoroethane used as a refrigerant, hence an exogenous origin is possible
2-propanol indoor air component in hospital rooms
2-propanol, 1,1,1-trichloro-2-methyl- exogenous origin?
acetamide, N,N-dimethyl- is released by Tedlar bags
acetic anhydride and acetyl bromide unclear origin
benzene, ethyl- potentially interesting compound, but one of the volatile BTEX-compounds (= benzene, toluene, ethyl-
benzene, xylene) appearing in gasoline
carbon disulfide is released by GCMS septa
cineole used in flavorings, fragrances, and cosmetics
diethyl ether suspected to be an indoor air component in hospital rooms
ethanol could be of exogenous origin
ethylene, tetrachloro- used in dry cleaning, hence an exogenous origin is possible
formamide, N,N -dimethyl- suspected to be an indoor air component in hospital rooms
isobutane exogenous origin? (propellant)
limonene exogenous origin? (is used in food manufacturing, cosmetics and cleansing agents)
p-cymene is contained in essential oils (e.g., in cumin and thyme)
m-cymene misidentification possible (mix-up with natural isomer p-cymene)
menthol mix of isomers might be contained in candies, toothpaste or foodstuff
methyl acetate is observed in healthy volunteers in low concentration (ca. 1 ppb), and increases with increased cardiac 
output
n-hexane there is an ubiquitous pollution with n-hexane in the environment
n-pentane marker for oxidative stress
p-xylene indoor air component in hospital rooms
pentane, 2-methyl- and pentane, 3-methyl potentially interesting compound, but might be released by GCMS septa
styrene styrene is sometimes added to the BTEX-compounds (see ethyl-benzene above), making it BTEXS
trichloroethylene TCE; groundwater contamination by TCE is an important environmental concern, hence an exogenous 
origin is possibleBMC Cancer 2009, 9:348 http://www.biomedcentral.com/1471-2407/9/348
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